Cartesian Therapeutics (NASDAQ:RNAC) Given Buy Rating at Needham & Company LLC
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating reissued by Needham & Company LLC in a note issued to investors on Monday,Benzinga reports. They currently have a $41.00 price target on the stock. Needham & Company LLC’s price target points to a potential upside of 117.28% from the company’s current price. […]
More Stories
Apple Business Manager: Login Process, Features, Pricing, and More
Apple Business Manager is a free web-based portal that helps businesses to manage, or you can say organize, different Apple...
Hawaii’s Big Island Prepares as Lala Strengthens to Hurricane Ahead of Possible Landfall
By Jeremy Lott Tropical Storm Lala has strengthened to a hurricane and could be the first to make landfall over...
US Tells EU ‘Now It’s Time to Deliver’ on Trade Commitments
By Bill Pan The United States is urging the European Union to further ease its corporate environmental rules, citing commitments...
Iran Accuses Qatar of Holding 3 of Its Military Pilots Captive
By Ryan Morgan The Iranian military, on Aug. 15, claimed three of its pilots are currently being held by Qatar,...
US Mortgage Rates Fall for First Time in 6 Weeks
By Naveen Athrappully The weekly average rate on a 30-year fixed-rate mortgage declined for the most recent week, breaking a...
What Battleground Voters Are Saying About Healthcare Affordability
By Lawrence Wilson “Yes, I do have opinions about this,” said Milwaukee resident Addaru Valentine just after voting in Wisconsin’s...